Aditxt, Inc. Net Fee Amt
Aditxt, Inc. (ADTX) had Net Fee Amt of $10.65 thousand as of 2026-04-09, per its S-3 filed 2026-04-13.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-13
- 2026-04-09: Net Fee Amt $10.65K.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-09 | $10.65K S-3 · filed 2026-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |